Plaque Psoriasis Efficacy and Safety With Secukinumab

Summary

To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.

Timeline

Start

2015-05-07

Primary completion

2017-03-14

Completion

2017-05-08

Drugs

Indications